Yale Bulletin and Calendar

January 26, 2001Volume 29, Number 16



BULLETIN HOME

VISITING ON CAMPUS

CALENDAR OF EVENTS

IN THE NEWS

BULLETIN BOARD

YALE SCOREBOARD

CLASSIFIED ADS


SEARCH ARCHIVES

PRODUCTION SCHEDULE

BULLETIN STAFF


PUBLIC AFFAIRS HOME

NEWS RELEASES

E-MAIL US


YALE HOME PAGE


Researchers now have both 'lock' and 'key' that can open door to reversing spinal, brain injuries

Researchers are one step closer to reversing brain and spinal cord injuries with the discovery of another molecule in a pathway that prevents axon regeneration, a Yale researcher says.

Dr. Stephen Strittmatter, who holds the Vincent Coates Chair in Neurology and is associate professor of neurology and neurobiology at the School of Medicine, says he and his collaborators have now identified the receptor responsible for inhibiting the growth of injured nerve fibers in the brain and spinal cord by the protein Nogo.

The finding could lead to the reversal of functional deficits in brain and spinal cord injuries caused by trauma and stroke, or brought about by degenerative diseases, such as multiple sclerosis.

"We had the key and now we have the lock," says Strittmatter, whose study was published Jan. 18 in the journal Nature. "The importance of the discovery is that by having both the ligand and the receptor molecules in hand, it greatly simplifies the search for inhibitors of that interaction and for therapeutic possibilities."

A year ago, Strittmatter and his collaborators published a study identifying the Nogo protein as one important and selective blocker of axon regeneration in the brain after central nervous system injury. Axons are the "telephone lines" of the nervous system, carrying a nerve impulse to a target cell.

"Once we had Nogo in hand, we needed to know: How does it function? How does it inhibit axon growth? We needed to identify the molecular mechanism of Nogo action," he says.

What the researchers found is a receptor on the axons to which the Nogo protein binds. It is this receptor, Strittmatter says, that inhibits the axon's regenerative growth.

"The current identification of a receptor mediating Nogo-66 action should greatly facilitate the development of agents with pharmaceutical potential in a diverse group of neurological conditions, such as spinal cord injury, brain trauma, stroke affecting white matter, and chronic, progressive multiple sclerosis," he says.

Collaborators on the study were Alyson Fournier, postdoctoral research fellow, and Tadzia GrandPre, graduate student.

-- By Jacqueline Weaver


T H I SW E E K ' SS T O R I E S

Dean David Kessler awarded Public Welfare Medal for leadership on health issues

Psychologist Karen Wynn cited for pioneering study . . .

New director of Beinecke Library named

Fossil sheds light on rare branch of birds' evolutionary tree

Yale-funded center helps bring start-up companies to city

Lilly Endowment grants will help fund initiatives at the Divinity School, ISM

Directors, actors take part in symposium on Irish film

'A Yale Album' captures century of history in photos

Benson reappointed to second term as dean of School of Art

Talks trace the evolution of the 'democratic soul'

Nuns' library donation reveals new aspects of artist's life

Beinecke exhibit explores 18th-century views of theater


MEDICAL SCHOOL NEWS

Illustrator is inaugural Theodore Fellow

Exhibition will feature paintings by Gelernter

Historian David Kennedy to discuss World War II

Grant supports nurse's effort to prevent diabetes in teens

ITS announces appointment of new CMI director

Art gallery appoints its first deputy director

Musicologist Claude Palisca, scholar of Baroque opera, dies



Bulletin Home|Visiting on Campus|Calendar of Events|In the News|Bulletin Board

Yale Scoreboard|Classified Ads|Search Archives|Production Schedule

Bulletin Staff|Public Affairs Home|News Releases| E-Mail Us|Yale Home Page